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background: I n this prospective study we investigated the long-term outcomes between Everolimus-eluting stents (EES) and Endeavor 
Zotarolimus-eluting stents (E-ZES), in patients with an isolated lesion in the proximal left anterior descending artery (pLAD) suffering from 
chronic stable angina.
methods:  We investigated 600 patients in a long-term follow up period up to 7 years. Of these, 420 patients underwent EES and 180 
E-ZES implantation. The primary end point was the incidence of Target Lesion Failure (TLF), a composite of cardiac deaths, myocardial 
infarctions and target lesion revascularizations (TLR). Secondary endpoints were the components of TLF and overall stent thrombosis. 
Statistical analysis was conducted with the Kaplan-Meier method.
results:  The median time of follow-up was 61 months. At 5 years, the cumulative probability of events were: TLF: EES: 7.5% vs E-ZES: 
13.8%, p=0.025, cardiac death: EES: 2.5% vs E-ZES: 3.1%, p=0.937, myocardial infarction: EES: 1.8% vs E-ZES: 1.2%, p = 0.829, TLR: 
EES: 3.3% vs E-ZES: 10.0%, p=0.003, stent thrombosis: EES: 2.7% vs E-ZES: 2.5%, p=0.965. The difference in probability of survival 
from TLF rose after 30 months (graphic).
Conclusion:  Both stents demonstrated a favourable safety profile, although this study is underpowered for generalised conclusions. 
Patients treated with EES demonstrated better clinical outcome in comparison with E-ZES and the difference emerged after 30 months of 
follow-up.
